{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:34:21Z","timestamp":1786365261928,"version":"build-2736575974"},"reference-count":42,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec id=\"st1\">\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The pediatric drug development landscape has experienced major shifts, largely in response to legislative and regulatory initiatives. However, associated laws and guidance documents fail to mandate the manufacture of pediatric formulations for commercial marketing post-regulatory approval. This study explores the nature of commercial products available at the time of pediatric labeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st2\">\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>All orally administered drugs for which labeling changes were made from 1998-2024 were evaluated. Characteristics of each drug\u2019s commercially marketed formulation(s) at the time of labeling were identified using product labeling (Drugs@FDA), Drugs.com, and DailyMed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st3\">\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>During the timeframe reviewed, there were 611 unique labeling changes representing 425 unique drugs available as 567 commercially marketed formulations. Of these drugs, 188 were marketed with pediatric-friendly (PF) formulations. The remainder were available only as solid oral dosage forms. For 329 pediatric labeling changes (53.8%), the only commercially marketed formulation was a solid oral dosage form, in many cases at sizes exceeding reasonable thresholds for the age group. For the remaining 282 labeling changes, a PF formulation was available alone or as a companion to the adult formulation. Among the PF formulations, 62% were suited to direct administration (liquid, orodispersible tablet, chewable\/paste, transmucosal) while the remainder required manipulation (i.e. powder\/granule, sprinkle\/pellet, dispersible tablet). Three-fourths of the PF formulations incorporated flavorings and aromas though 13% failed to report the use of sweeteners.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st4\">\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Less than complete access to PF formulations requires attention if we are to maximize the provision of suitable pharmacotherapy for pediatric patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5863\/jppt-25-00141","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:26:13Z","timestamp":1786364773000},"page":"493-500","source":"Crossref","is-referenced-by-count":0,"title":["Suitability of Oral Formulations Available to Children at the Time of Pediatric Labeling"],"prefix":"10.5863","volume":"31","author":[{"given":"Susan M.","family":"Abdel-Rahman","sequence":"first","affiliation":[{"name":"Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (SMA, GB); Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie A.","family":"Avant","sequence":"additional","affiliation":[{"name":"Office of Pediatric Therapeutics, Office of the Commissioner, U.S. Food and Drug Administration (DA) Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert J.","family":"Burckart","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (SMA, GB); Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"Jun 3","key":"JPPT-25-00141-b01","series-title":"Front Pharmacol","first-page":"1375988","article-title":"Reflections on the regulatory field covering the development of paediatric medicinal products: a brief overview of current status and challenges","volume":"15","author":"Lehmann","year":"2024","unstructured":"Lehmann B. Reflections on the regulatory field covering the development of paediatric medicinal products: a brief overview of current status and challenges. Front Pharmacol. 2024;15(Jun 3):1375988."},{"key":"JPPT-25-00141-b02","series-title":"Adv Drug Deliv Rev","first-page":"2","article-title":"Paediatric drug development: the impact of evolving regulations","volume":"73","author":"Turner","year":"2014","unstructured":"Turner MA, Catapano M, Hirschfeld S, Giaquinto C; Global Research in Paediatrics. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev. 2014; 73:2\u201313."},{"key":"JPPT-25-00141-b03","series-title":"Pub L No. 107-109, 107th Congress, 115 Stat 1408","year":"2002","unstructured":"Best Pharmaceuticals for Children Act. Pub L No. 107-109, 107th Congress, 115 Stat 1408 (2002). Accessed January 29, 2025. https:\/\/www.congress.gov\/107\/plaws\/publ109\/PLAW-107publ109.pdf"},{"key":"JPPT-25-00141-b04","series-title":"Pub L No. 108-155, 108th Congress, 117 Stat 1936","year":"2003","unstructured":"Pediatric Research Equity Act. Pub L No. 108-155, 108th Congress, 117 Stat 1936 (2003). Accessed January 29, 2025. https:\/\/www.congress.gov\/108\/plaws\/publ155\/PLAW-108publ155.pdf"},{"key":"JPPT-25-00141-b05","series-title":"Pub L No. 112-144, 112th Congress, 126 Stat 993","year":"2012","unstructured":"Food and Drug Administration Safety and Innovation Act. Pub L No. 112-144, 112th Congress, 126 Stat 993 (2012). Accessed January 29, 2025. https:\/\/www.congress.gov\/112\/plaws\/publ144\/PLAW-112publ144.pdf"},{"key":"JPPT-25-00141-b06","series-title":"Updates to Pediatric Drug Development Guidelines in Japan","author":"Yakugyo","year":"2024-05-01","unstructured":"Yakugyo N. Updates to Pediatric Drug Development Guidelines in Japan. 2024-05-01. https:\/\/idec-inc.com\/blog\/2024\/05\/01\/updates-to-pediatric-drug-development-guidelines-in-japan\/#:\u223c:text=In%20response%20to%20a%20question,relies%20on%20a%20corporate%20decision [accessed 18 April 2025]"},{"key":"JPPT-25-00141-b07","series-title":"Guidance on submitting pediatric development plans and pediatric studies","year":"2024-02-26","unstructured":"Health Canada. Guidance on submitting pediatric development plans and pediatric studies. 2024-02-26. https:\/\/publications.gc.ca\/site\/archivee-archived.html?url=https:\/\/publications.gc.ca\/collections\/collection_2024\/sc-hc\/H164-362-2024-eng.pdf [accessed 18 April 2025]"},{"key":"JPPT-25-00141-b08","series-title":"Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use","unstructured":"European Union. Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use . Accessed January 29, 2025. https:\/\/eur-lex.europa.eu\/eli\/reg\/2006\/1901\/oj\/eng"},{"issue":"4","key":"JPPT-25-00141-b09","series-title":"Arch Dis Child","first-page":"317","article-title":"WHO essential medicines for children 2011-2019: age-appropriateness of enteral formulations","volume":"107","author":"Orubu","year":"2022","unstructured":"Orubu ESF, Duncan J, Tuleu C, et al. WHO essential medicines for children 2011-2019: age-appropriateness of enteral formulations. Arch Dis Child. 2022;107(4):317\u2013322."},{"issue":"6","key":"JPPT-25-00141-b10","series-title":"Int J Clin Pharm","first-page":"1394","article-title":"Development and evaluation of an assessment of the age-appropriateness\/inappropriateness of formulations used in children","volume":"44","author":"Duncan","year":"2022","unstructured":"Duncan JC, Bracken LE, Nunn AJ, et al. Development and evaluation of an assessment of the age-appropriateness\/inappropriateness of formulations used in children. Int J Clin Pharm. 2022;44(6):1394\u20131405."},{"key":"JPPT-25-00141-b11","series-title":"Pediatric Formulations","year":"2025","unstructured":"European Medicines Agency. Pediatric Formulations. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-and-development\/paediatric-medicines-research-and-development\/paediatric-investigation-plans\/paediatric-formulations [accessed 18 April 2025]"},{"issue":"4","key":"JPPT-25-00141-b12","series-title":"AAPS J","first-page":"1072","article-title":"A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms","volume":"15","author":"Zajicek","year":"2013","unstructured":"Zajicek A, Fossler MJ, Barrett JS, et al. A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. AAPS J. 2013;15(4):1072\u201381."},{"key":"JPPT-25-00141-b13","series-title":"Pediatric Labeling Changes","year":"03\/06\/2024","unstructured":"U.S. Food and Drug Administration. Pediatric Labeling Changes. 03\/06\/2024. https:\/\/www.fda.gov\/science-research\/pediatrics\/pediatric-labeling-changes [accessed 29 January 2025]"},{"key":"JPPT-25-00141-b14","series-title":"Drugs@FDA","year":"2025","unstructured":"U.S. Food and Drug Administration. Drugs@FDA. 2025. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm [accessed 06 October 2025]"},{"key":"JPPT-25-00141-b15","series-title":"FDA Label","year":"2025","unstructured":"U.S. Food and Drug Administration. FDA Label. 2025. https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/search [accessed 06 October 2025]"},{"key":"JPPT-25-00141-b16","year":"2025","unstructured":"Drugs.Com. 2025. https:\/\/www.drugs.com\/ [accessed 06 October 2025]"},{"key":"JPPT-25-00141-b17","series-title":"DailyMed","year":"2025","unstructured":"National Institutes of Health, National Library of Medicine. DailyMed. 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/ [accessed 06 October 2025]"},{"issue":"4","key":"JPPT-25-00141-b18","series-title":"Pharmaceutics","first-page":"1033","article-title":"Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children","volume":"15","author":"Golhen","year":"2023","unstructured":"Golhen K, Buettcher M, Kost J, et al. Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children. Pharmaceutics. 2023;15(4):1033."},{"issue":"1","key":"JPPT-25-00141-b19","series-title":"Expert Rev Clin Pharmacol","first-page":"25","article-title":"Pediatric formulation issues identified in Paediatric Investigation Plans","volume":"7","author":"Quijano Ruiz","year":"2014","unstructured":"Quijano Ruiz B, Desfontaine E, Arenas-L\u00f3pez S, Wang S. Pediatric formulation issues identified in Paediatric Investigation Plans. Expert Rev Clin Pharmacol. 2014;7(1):25\u201330."},{"issue":"6","key":"JPPT-25-00141-b20","series-title":"PLoS One","first-page":"e98348","article-title":"Oral medicines for children in the European paediatric investigation plans","volume":"9","author":"van Riet-Nales","year":"2014","unstructured":"van Riet-Nales DA, R\u00f6mkens EG, Saint-Raymond A, et al. Oral medicines for children in the European paediatric investigation plans. PLoS One. 2014;9(6):e98348."},{"issue":"1","key":"JPPT-25-00141-b21","series-title":"Int J Pharm","first-page":"296","article-title":"Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children's Acceptability of Oral Formulations (CALF) Study","volume":"514","author":"Ranmal","year":"2016","unstructured":"Ranmal SR, Cram A, Tuleu C. Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children's Acceptability of Oral Formulations (CALF) Study. Int J Pharm. 2016;514(1):296\u2013307."},{"issue":"3","key":"JPPT-25-00141-b22","series-title":"Obesity (Silver Spring)","first-page":"E190","article-title":"Adherence to vitamin supplementation following adolescent bariatric surgery","volume":"21","author":"Modi","year":"2013","unstructured":"Modi AC, Zeller MH, Xanthakos SA, et al. Adherence to vitamin supplementation following adolescent bariatric surgery. Obesity (Silver Spring). 2013;21(3):E190\u20135."},{"issue":"9","key":"JPPT-25-00141-b23","series-title":"J Pediatr Psychol","first-page":"1005","article-title":"Brief report: Barriers to treatment adherence in pediatric inflammatory bowel disease","volume":"35","author":"Hommel","year":"2010","unstructured":"Hommel KA, Baldassano RN. Brief report: Barriers to treatment adherence in pediatric inflammatory bowel disease. J Pediatr Psychol. 2010;35(9):1005\u201310."},{"issue":"1","key":"JPPT-25-00141-b24","series-title":"Paediatr Drugs","first-page":"65","article-title":"Tablet\/Capsule Size Variation Among the Most Commonly Prescribed Medications for Children in the USA: Retrospective Review and Firsthand Pharmacy Audit","volume":"18","author":"Jacobsen","year":"2016","unstructured":"Jacobsen L, Riley K, Lee B, et al. Tablet\/Capsule Size Variation Among the Most Commonly Prescribed Medications for Children in the USA: Retrospective Review and Firsthand Pharmacy Audit. Paediatr Drugs. 2016;18(1):65\u201373."},{"key":"JPPT-25-00141-b25","series-title":"Guidance For Industry. Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules","year":"2015","unstructured":"U.S. Food and Drug Administration. Guidance For Industry. Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules. 2015. Available at: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm377938.pdf [accessed 23 April 2025]."},{"key":"JPPT-25-00141-b26","series-title":"Guideline on Pharmaceutical Development of Medicines for Paediatric Use Draft (EMA\/CHMP\/QWP\/180157\/2011)","year":"19 May 2011","unstructured":"European Medicines Agency. Guideline on Pharmaceutical Development of Medicines for Paediatric Use Draft (EMA\/CHMP\/QWP\/180157\/2011). 19 May 2011. https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwiz9Ivwve6MAxUKnokEHbd_O7gQFnoECBoQAQ&url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fscientific-guideline%2Fdraft-guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf-0&usg=AOvVaw3aoclBkP2W5u9xliO4bXf8&opi=89978449 [accessed 23 April 2025]"},{"issue":"5","key":"JPPT-25-00141-b27","series-title":"Clin Pharmacol Ther","first-page":"582","article-title":"Demonstrating evidence of acceptability: the \u201ccatch-22\u201d of pediatric formulation development","volume":"94","author":"Ranmal","year":"2013","unstructured":"Ranmal S, Tuleu C. Demonstrating evidence of acceptability: the \u201ccatch-22\u201d of pediatric formulation development. Clin Pharmacol Ther 2013;94(5):582\u20134."},{"issue":"5","key":"JPPT-25-00141-b28","series-title":"Paediatr Anaesth","first-page":"531","article-title":"The feasibility of pain treatment at home after adenoidectomy with ketoprofen tablets in small children","volume":"10","author":"Kokki","year":"2000","unstructured":"Kokki H, Nikanne E, Ahonen R. The feasibility of pain treatment at home after adenoidectomy with ketoprofen tablets in small children. Paediatr Anaesth. 2000;10(5):531\u20135."},{"issue":"8","key":"JPPT-25-00141-b29","series-title":"Clin Pediatr (Phila)","first-page":"725","article-title":"Pill swallowing ability and training in children 6 to 11 years of age","volume":"45","author":"Meltzer","year":"2006","unstructured":"Meltzer EO, Welch MJ, Ostrom NK. Pill swallowing ability and training in children 6 to 11 years of age. Clin Pediatr (Phila). 2006;45(8):725\u201333."},{"issue":"3","key":"JPPT-25-00141-b30","series-title":"Arch Dis Child","first-page":"283","article-title":"Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study","volume":"97","author":"Spomer","year":"2012","unstructured":"Spomer N, Klingmann V, Stoltenberg I, et al. Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch Dis Child. 2012;97(3):283\u20136."},{"issue":"5","key":"JPPT-25-00141-b31","series-title":"PLoS One","first-page":"e36186","article-title":"Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa","volume":"7","author":"Nahirya-Ntege","year":"2012","unstructured":"Nahirya-Ntege P, Cook A, Vhembo T, et al. Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One. 2012;7(5):e36186."},{"issue":"11","key":"JPPT-25-00141-b32","series-title":"South Med J","first-page":"1106","article-title":"Parental report of medication acceptance among youth: implications for everyday practice","volume":"101","author":"Polaha","year":"2008","unstructured":"Polaha J, Dalton WT 3rd, Lancaster BM. Parental report of medication acceptance among youth: implications for everyday practice. South Med J. 2008;101(11):1106\u201312."},{"issue":"2","key":"JPPT-25-00141-b33","series-title":"Southeast Asian J Trop Med Public Health","first-page":"334","article-title":"Acceptability of oral typhoid vaccine in Thai children","volume":"34","author":"Mekmullica","year":"2003","unstructured":"Mekmullica J, Pancharoen C. Acceptability of oral typhoid vaccine in Thai children. Southeast Asian J Trop Med Public Health. 2003;34(2):334\u20136."},{"issue":"5","key":"JPPT-25-00141-b34","series-title":"Paediatr Child Health","first-page":"e1\u20135","article-title":"Successful treatment of pill-swallowing difficulties with head posture practice","volume":"15","author":"Kaplan","year":"2010","unstructured":"Kaplan BJ, Steiger RA, Pope J, et al. Successful treatment of pill-swallowing difficulties with head posture practice. Paediatr Child Health. 2010;15(5):e1\u20135."},{"issue":"1","key":"JPPT-25-00141-b35","series-title":"Pharmaceuticals (Basel)","first-page":"108","article-title":"Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics","volume":"15","author":"Zuccari","year":"2022","unstructured":"Zuccari G, Alfei S, Marimpietri D, et al. Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics. Pharmaceuticals (Basel). 2022;15(1):108."},{"key":"JPPT-25-00141-b36","series-title":"J Pediatr","first-page":"202","article-title":"Acceptability of Multiple Uncoated Minitablets in Infants and Toddlers: A Randomized Controlled Trial","volume":"201","author":"Klingmann","year":"2018","unstructured":"Klingmann V, Linderskamp H, Meissner T, et al. Acceptability of Multiple Uncoated Minitablets in Infants and Toddlers: A Randomized Controlled Trial. J Pediatr. 2018;201:202\u2013207."},{"issue":"8","key":"JPPT-25-00141-b37","series-title":"J Okla State Med Assoc","first-page":"776","article-title":"Off-Label Medication use in Children, More Common than We Think: A Systematic Review of the Literature","volume":"111","author":"Allen","year":"2018","unstructured":"Allen HC, Garbe MC, Lees J, et al. Off-Label Medication use in Children, More Common than We Think: A Systematic Review of the Literature. J Okla State Med Assoc. 2018;111(8):776\u2013783."},{"issue":"1","key":"JPPT-25-00141-b38","series-title":"Int J Risk Saf Med","first-page":"77","article-title":"Global research publications on systemic use of off-label and unlicensed drugs: A bibliometric analysis (1990\u20132020)","volume":"33","author":"Sweileh","year":"2022","unstructured":"Sweileh WM. Global research publications on systemic use of off-label and unlicensed drugs: A bibliometric analysis (1990\u20132020). Int J Risk Saf Med. 2022;33(1):77\u201389."},{"issue":"6","key":"JPPT-25-00141-b39","series-title":"World J Pediatr","first-page":"528","article-title":"Two decades of off-label prescribing in children: a literature review","volume":"14","author":"Balan","year":"2018","unstructured":"Balan S, Hassali MAA, Mak VSL. Two decades of off-label prescribing in children: a literature review. World J Pediatr. 2018;14(6):528\u2013540."},{"key":"JPPT-25-00141-b40","series-title":"Eur J Pharm Biopharm","first-page":"114483","article-title":"Pediatric oral extemporaneous preparations and practices: International Pharmaceutical Federation (FIP) global study","volume":"204","author":"Fadda","year":"2024","unstructured":"Fadda HM, Weiler H, Carvalho M, et al. Pediatric oral extemporaneous preparations and practices: International Pharmaceutical Federation (FIP) global study. Eur J Pharm Biopharm. 2024;204:114483."},{"issue":"12","key":"JPPT-25-00141-b41","series-title":"Children","first-page":"1885","article-title":"How Compounding Pharmacies Fill Critical Gaps in Pediatric Drug Development Processes: Suggested Regulatory Changes to Meet Future Challenges","volume":"9","author":"MacArthur","year":"2022","unstructured":"MacArthur RB, Ashworth LD, Zhan K, Parrish RH II. How Compounding Pharmacies Fill Critical Gaps in Pediatric Drug Development Processes: Suggested Regulatory Changes to Meet Future Challenges. Children. 2022;9(12):1885."},{"issue":"3","key":"JPPT-25-00141-b42","series-title":"Pharmaceutics","first-page":"840","article-title":"Prevalence, Risk, and Challenges of Extemporaneous Preparation for Pediatric Patients in Developing Nations: A Review","volume":"15","author":"Yuliani","year":"2023","unstructured":"Yuliani SH, Putri DCA, Virginia DM, et al. Prevalence, Risk, and Challenges of Extemporaneous Preparation for Pediatric Patients in Developing Nations: A Review. Pharmaceutics. 2023;15(3):840."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/4\/article-p493.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/4\/article-p493.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/4\/article-p493.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:26:13Z","timestamp":1786364773000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/4\/article-p493.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/jppt-25-00141","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}